Source comparison
TB-500 vs BPC-157 vs Growth Hormone: Post-Surgery Recovery Comparison
TB-500 (Thymosin Beta-4) Actin polymerization, angiogenesis, reduced fibrosis Tendon, ligament, muscle repair 2–5 mg twice weekly for 4–6 weeks Moderate. Animal models strong, human trials limited Most targeted for soft tissue remodeling; reduces scar tissue f
This comparison does not assign a generated winner or score.
- TB-500 (Thymosin Beta-4)
- Actin polymerization, angiogenesis, reduced fibrosis
- Tendon, ligament, muscle repair
- 2–5 mg twice weekly for 4–6 weeks
- Moderate. Animal models strong, human trials limited
- Most targeted for soft tissue remodeling; reduces scar tissue formation
- BPC-157 (Body Protection Compound)
- Promotes VEGF, modulates nitric oxide, stabilizes GI mucosal integrity
- GI tract repair, systemic inflammation
- 250–500 mcg daily for 4–8 weeks
- Weak. Mostly rodent studies, no Phase II human trials
- Broader systemic effects but less tissue-specific than TB-500
- Growth Hormone (GH)
- IGF-1 upregulation, protein synthesis, lipolysis
- Muscle wasting, catabolic states
- 2–4 IU daily for 12+ weeks
- Strong. FDA-approved for specific indications
- Effective for muscle preservation but not targeted to wound healing per se
- IGF-1 LR3
- Direct IGF-1 receptor activation, hyperplasia
- Muscle hypertrophy, nitrogen retention
- 40–80 mcg daily for 4 weeks
- Weak. Veterinary use only, no human trials
- More anabolic than regenerative; not ideal for post-surgical contexts
- Collagen Peptides (oral)
- Provides amino acids for collagen synthesis
- General connective tissue support
- 10–20 g daily ongoing
- Moderate. Clinical trials show benefit in joint health
- Supportive but indirect; does not replace targeted peptide intervention